Clinical trials: Stage IIIA Skin Melanoma
Melanoma (Skin)
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine.
- Trial name
- NCT01176461
- Testing
- MART-1, NY-ESO-1, gp100:209-217(210M)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Colorectal Cancer
Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating patients who have had surgery for…
- Conditions
- Breast Cancer, Colorectal Cancer, Melanoma (Skin)
- Trial name
- NCT00002455
- Testing
- Corynebacterium granulosum P40, adjuvant therapy
- Where
- Argentina
- Sponsor
- Centro Oncologico de Excelencia
Hereditary Multiple Melanoma, Melanoma (Skin)
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer.
- Trial name
- NCT00450593
- Testing
- gene expression analysis, microarray analysis, molecular genetic technique
- Where
- United Kingdom
- Volunteers
- 5,000 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Advanced Malignant Solid Neoplasm, Recurrent Melanoma
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with riluzole in treating patients with solid tumors or melanoma that has spread to other places in the body and usually cannot…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Melanoma, Refractory Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01303341
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Riluzole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
The purpose of this study is to compare the drug levels, immunogenicity and safety of Nivolumab Process D to Nivolumab Process C after complete resection of stage IIIa/b/c/d or stage IV melanoma.
- Trial name
- NCT03980314
- Testing
- Nivolumab
- Where
- 37 sites in United States, Argentina and 12 more
- Volunteers
- 261 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Melanoma, Stage IIIA Melanoma
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
This phase II trial studies how well high-dose aldesleukin and ipilimumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02203604
- Testing
- aldesleukin, ipilimumab, laboratory biomarker analysis
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- CINJRegulatory
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells.
- Conditions
- Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma
- Trial name
- NCT02748564
- Testing
- Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's dendritic cells mixed with tumor peptides and proteins may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00390338
- Testing
- polarized dendritic cells, non-polarized dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pawel Kalinski
Melanoma (Skin)
Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma
RATIONALE: Gathering information about vitamin D supplementation and sun exposure in patients with melanoma may help doctors learn more about the disease and find what may affect cancer relapse.
- Trial name
- NCT00672321
- Testing
- gene expression analysis, mutation analysis, polymorphism analysis
- Where
- United Kingdom
- Volunteers
- 2,774 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Stage IA Skin Melanoma, Stage IB Skin Melanoma
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
This pilot clinical trial studies recombinant interferon alfa-2b in treating patients with melanoma. Recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma
- Conditions
- Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
- Trial name
- NCT01460875
- Testing
- recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- William Carson
Stage IIA Skin Melanoma, Stage IIB Skin Melanoma
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating…
- Conditions
- Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT02320305
- Testing
- MART-1 Antigen, TLR4 Agonist GLA-SE, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Acral Lentiginous Malignant Melanoma, Recurrent Melanoma
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Acral Lentiginous Malignant Melanoma, Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT00470470
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
This randomized pilot phase I trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 when given together with nivolumab or ipilimumab in treating patients with stage III or IV melanoma.
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7
- Trial name
- NCT03425461
- Testing
- Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
This phase II trial studies whether rituximab and hyaluronidase human (Rituxan Hycela) can prevent immune related adverse events in participants with stage III-IV melanoma that cannot be removed by surgery who are undergoing…
- Conditions
- Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma
- Trial name
- NCT03719131
- Testing
- Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Emory University
Stage IB Skin Melanoma, Stage IIA Skin Melanoma
Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy
This pilot clinical trial studies intravital microscopy in identifying tumor vessels in patients with stage IB-IIIC melanoma undergoing sentinel lymph node biopsy.
- Conditions
- Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma
- Trial name
- NCT02857374
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Melanoma, Stage IIA Melanoma
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with stage II-IV melanoma that has been removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT01748747
- Testing
- Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of onalespib when given together with dabrafenib and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that have spread to another place in the…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02097225
- Testing
- Dabrafenib, Laboratory Biomarker Analysis, Onalespib
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
This study evaluates the immune related toxicity and symptom burden in chronic cancer survivors with melanoma who are receiving adjuvant immunotherapy with immune checkpoint inhibitors.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT04990726
- Testing
- Assessment, Biospecimen Collection, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center